Neogenomics (NEO) Notes Payables (2024 - 2025)

Neogenomics' (NEO) quarterly Notes Payables came in at $201.1 million in Q1 2025, little changed on a QoQ basis from $200.8 million in Q4 2024.

Neogenomics (NEO) Notes Payables (2024 - 2025) Analysis & Trends

Neogenomics (NEO) has 2 years of Notes Payables data on file, last reported at $201.1 million in Q1 2025.

Quarterly Notes Payables changed N/A year-over-year to $201.1 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $201.1 million (changed N/A YoY) and the FY2024 annual result came in at $200.8 million, changed N/A from the prior year.
Notes Payables held at $201.1 million in Q1 2025, from $200.8 million in the prior quarter.
In the past five years, Notes Payables ranged from a high of $201.1 million in Q1 2025 to a low of $200.1 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Thermo Fisher Scientific	234.15 Bn	230.09 Bn	8.34 Bn
2	Danaher	152.10 Bn	147.75 Bn	3.61 Bn
3	Natera	48.48 Bn	47.38 Bn	486.15 Mn
4	Agilent Technologies	44.35 Bn	42.55 Bn	990.00 Mn
5	Iqvia Holdings	43.68 Bn	41.60 Bn	1.44 Bn
6	Idexx Laboratories	43.02 Bn	42.83 Bn	779.09 Mn
7	Illumina	34.39 Bn	33.22 Bn	770.00 Mn
8	Mettler Toledo International	28.29 Bn	28.24 Bn	650.22 Mn
9	Labcorp Holdings	27.51 Bn	27.37 Bn	1.11 Bn
10	Neogenomics	2.42 Bn	2.28 Bn	91.88 Mn

Download Data